28.80
+0.11
(0.38%)
Jun 19 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 28.56 - 29.25 |
| 52 week | 19.58 - 31.36 |
| Open | 28.70 |
| Vol / Avg. | 895,941.00/720,091.00 |
| Mkt cap | 1.88B |
| P/E | - |
| Div/yield | - |
| EPS | -1.19 |
| Shares | 65.31M |
| Beta | 1.55 |
| Inst. own | 107% |
Events
Aug 5, 2013
Q2 2013 ViroPharma Earnings Release
Jun 18, 2013
ViroPharma at Wells Fargo Health Care Conference
Jun 11, 2013
ViroPharma at Goldman Sachs Healthcare Conference
Jun 5, 2013
ViroPharma at Jefferies Global Healthcare Conference
May 29, 2013
ViroPharma at Deutsche Bank dbAccess Health Care Conference
May 23, 2013
ViroPharma Annual Shareholder Meeting
May 14, 2013
ViroPharma at Bank of America Merrill Lynch Health Care Conference
May 1, 2013
Q1 2013 ViroPharma Earnings Conference Call
Apr 29, 2013
Q1 2013 ViroPharma Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -59.73% | 1.31% |
| Operating margin | -91.33% | 7.79% |
| EBITD margin | - | 16.72% |
| Return on average assets | -22.05% | 0.44% |
| Return on average equity | -35.22% | 0.68% |
| Employees | 410 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
ViroPharma Incorporated (ViroPharma) is an international biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). The Company is also developing VP20621 for the treatment and prevention of CDAD.
Officers and directors
| Vincent J. Milano | Chairman of the Board, President, Chief Executive Officer | |
| Charles A. Rowland Jr. | Chief Financial Officer, Vice President | |
| Daniel B. Soland | Vice President, Chief Operating Officer | |
| John J. Kirby | Chief Accounting Officer, Vice President | |
| Colin Broom M.D. | Vice President, Chief Scientific Officer | |
| Robert C. Fletcher | Vice President - Business Development and Project Management | |
| John Peter Wolf | Vice President, General Counsel, Secretary | |
| Thomas F. Doyle | Vice President - Strategic Initiatives | |
| Robert G. Pietrusko | Vice President - Global Regulatory Affairs and Quality | |
| Howard H Pien | Lead Independent Director |